A child with newly diagnosed high-risk B-cell acute lymphoblastic leukemia has completed consolidation therapy. The treating team is considering whether evidence supports replacing two cycles of conventional chemotherapy with blinatumomab.
What does the evidence in this abstract support for children with newly diagnosed high-risk B-cell ALL after consolidation?